STERIS’ (TSE:STE – Free Report) – Investment analysts at Raymond James dropped their FY2026 earnings per share (EPS) estimates for shares of STERIS’ in a research note issued to investors on Wednesday, April 9th. Raymond James analyst M. Barth now expects that the company will post earnings per share of $0.48 for the year, down from their prior estimate of $0.72. Raymond James currently has a “Hold” rating on the stock.
A number of other research firms have also recently weighed in on STE. Atb Cap Markets raised shares of STERIS’ to a “strong-buy” rating in a research report on Sunday, December 22nd. Cormark upgraded STERIS’ to a “moderate buy” rating in a research report on Monday, January 6th.
STERIS’ Stock Performance
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Featured Stories
- Five stocks we like better than STERIS’
- Stock Sentiment Analysis: How it Works
- Beware of BigBear.ai: Insiders Are Selling—Should You?
- Insider Trading – What You Need to Know
- CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
- How to Profit From Value Investing
- Congress! Who Traded What During the Tariff-Induced Meltdown
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
